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Background: Tuberculous meningitis (TBM), the most severe form of 
tuberculosis (TB), results in death or neurological disability in >50%, 
despite World Health Organisation recommended therapy. Current 
TBM regimen dosages are based on data from pulmonary TB alone. 
Evidence from recent phase II pharmacokinetic studies suggests that 
high dose rifampicin (R) administered intravenously or orally 
enhances central nervous system penetration and may reduce TBM 
associated mortality. We hypothesize that, among persons with TBM, 
high dose oral rifampicin (35 mg/kg) for 8 weeks will improve survival 
compared to standard of care (10 mg/kg), without excess adverse 
events. 
Protocol: We will perform a parallel group, randomised, placebo-
controlled, double blind, phase III multicentre clinical trial comparing 
high dose oral rifampicin to standard of care. The trial will be 
conducted across five clinical sites in Uganda, South Africa and 
Indonesia. Participants are HIV-positive or negative adults with 
clinically suspected TBM, who will be randomised (1:1) to one of two 
arms: 35 mg/kg oral rifampicin daily for 8 weeks (in combination with 
standard dose isoniazid [H], pyrazinamide [Z] and ethambutol [E]) or 
standard of care (oral HRZE, containing 10 mg/kg/day rifampicin). The 
primary end-point is 6-month survival. Secondary end points are: i) 12-
month survival ii) functional and neurocognitive outcomes and iii) 
safety and tolerability. Tertiary outcomes are: i) pharmacokinetic 
outcomes and ii) cost-effectiveness of the intervention. We will enrol 
500 participants over 2.5 years, with follow-up continuing until 12 
months post-enrolment. 
Discussion: Our best TBM treatment still results in unacceptably high 
mortality and morbidity. Strong evidence supports the increased 
cerebrospinal fluid penetration of high dose rifampicin, however 
conclusive evidence regarding survival benefit is lacking. This study 
will answer the important question of whether high dose oral 
rifampicin conveys a survival benefit in TBM in HIV-positive and -
negative individuals from Africa and Asia. 
Trial registration: ISRCTN15668391 (17/06/2019)
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Introduction
Disease burden and prognosis
Tuberculosis (TB) was the leading cause of mortality world-
wide from a single infectious agent and, in 2018, 10 million 
cases were reported globally1. Tuberculous meningitis (TBM) 
accounts for approximately 1% of global TB cases but has a 
profound impact due to its high morbidity and mortality2; 
19–28% of HIV-negative3 and 40–58% of HIV-positive patients 
die during treatment4,5 and half of survivors suffer neurologic 
disability6. This results in a high burden to health care systems 
and caregivers with prolonged hospital admissions and 
rehabilitation periods. There is estimated to be 100 000 cases 
worldwide annually, but due to inaccurate diagnostics and 
scarce epidemiological data in many TB endemic regions this 
figure is likely an underestimate2,7. TBM disproportionately 
affects those in high TB prevalence countries, children under 
5 years of age and those with HIV coinfection2. It is the second 
leading cause of meningitis in in hospitalised adults in South 
Africa and Uganda8,9, and the leading cause of adult meningitis 
among those admitted to neurology wards in Indonesia (Table 1)10.
Treatment
Current World Health Organisation (WHO) recommended 
therapy consists of rifampicin, isoniazid, pyrazinamide and 
ethambutol for two months (intensive phase), followed by 
rifampicin and isoniazid alone to complete 9–12 months (con-
tinuation phase). Factors known to improve survival include 
early TB treatment initiation and adjunctive corticosteroids11. 
Nevertheless, morbidity and mortality remains unacceptably 
high12, likely in part due to delays in seeking medical care, 
diagnosis and initiation of treatment. Current drug choice, dose 
and routes of administration for TBM treatment are based on 
principles used for pulmonary TB (PTB)13,14. However, unlike 
PTB, antibiotics to treat TBM must cross the blood-brain 
barrier (BBB) or blood-cerebrospinal fluid-barrier (BCSFB). 
Therefore, another possible contributory factor towards mortality 
in TBM may be poor central nervous system (CNS) penetration 
of vital TB drugs15.
Factors affecting drug entry into the brain and CSF include lipid 
solubility, ionisation, molecular weight, protein binding and 
processes of active transport. Meningeal inflammation also 
impacts cell tight junction integrity and therefore drug levels in 
the brain and CSF. Due to variable TB drug penetration across 
the BCSFB and BBB (Figure 1), optimal treatment regimens 
for PTB may not be most effective for TBM. It follows, that 
altering drug selection, dosing and route of administration may 
improve treatment outcomes by ensuring adequate delivery to 
the site of disease and early mycobacterial activity in the CNS15.
Limitations of standard dose rifampicin
Rifampicin forms the backbone of TBM treatment, and is 
believed to be the most critical drug in the treatment of 
TB, as supported by the near-universal fatal outcome 
reported in patients infected with rifampicin and isoniazid 
resistant Mycobacterium tuberculosis strains (multidrug resistant 
(MDR)-TB)16,17. While some excess mortality may be explained 
by delayed diagnosis of rifampicin resistance, mortality remains 
greater than 75% in patients diagnosed early enough that 
second-line drugs can be initiated17,18.
In plasma, the historical recommended target peak concentra-
tions of rifampicin are 8-24mg/L. This historical target is based 
on rifampicin concentrations typically observed in healthy adults 
(i.e. the reference range after a dose of 10mg/kg orally), and 
is not optimized based on pharmacokinetic-pharmacodynamic 
(PK-PD) data19. In is now accepted that total exposure to TB drugs, 
or the area under the 24-h concentration–time curve (AUC
0–24
), 
is more relevant to the efficacy of first-line TB drugs. Ideally, 
AUC
0–24
 is considered together with the minimum inhibitory con-
centration (MIC) of the mycobacteria to yield an AUC
0–24
/MIC 
ratio that is supposed to best predict response in murine 
models20. A large meta-analysis of rifampicin pharmacokinetic data 








Bacterial TBM Cryptococcal Other / Unknown
Kampala / 
Mbarara8 Uganda 416 98% 4% 8% 59% 29%
Cape Town9 S. Africa 1,737 96% 19% 13% 30% 38%
Jakarta10 Indonesia 274 54% 0% 34% 5% 61%
TBM = tuberculous meningitis
     Amendments from Version 1
We have noted the comments from both reviewers and added 
further detail to the Introduction about the rationale for the 
choice of rifampicin dose based on studies from pulmonary TB 
and TBM.
We have also added recent data about rifampicin in brain tissue 
from a rabbit model and the findings of the PK-PD study from the 
large Vietnamese Intensified treatment trial.
We have removed an asterisk from Table 1 as it was incorrectly 
included in the version 1.
We mention to Intense-TBM trial in the Discussion.
Any further responses from the reviewers can be found at 
the end of the article
REVISED
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Figure 1. Schematic overview of the blood-brain barrier (brain endothelial cells) and the blood-CSF barrier (choroid plexus 
epithelial cells). Reproduced with permission from Cresswell et al.21.
amongst TB patients found that the mean plasma rifampicin peak 
concentration at steady state is only 5.79mg/L (below the histori-
cal target concentration) and doses of >25mg/kg are needed to 
achieve the PK-PD target derived from murine studies (AUC/MIC 
>271)22. Animal and human pharmacokinetic-pharmacodynamic 
(PK-PD) studies suggest that plasma rifampicin exposure at cur-
rent dosing (10 mg/kg) provides exposure that it is sub-optimal 
in most patients23.
CSF rifampicin concentration is reported to approximately 
12% of total (protein-bound plus unbound) plasma concen-
trations and approximately 50% based on estimated unbound 
concentrations24–26. The standard dose of rifampicin is known 
to often result in CSF concentration below or around the 
M. tuberculosis minimum inhibitory concentration (MIC) for 
rifampicin of 0.2–0.4 mg/L15. In fact, CSF rifampicin concen-
trations were below the level of detection in approximately 
67% of Indonesian patients with TBM receiving standard oral 
adult dose (8–10mg/kg)27.
Additional factors may affect rifampicin exposure in TBM 
patients. For example, HIV co-infection may influence the 
concentrations of rifampicin achieved in the plasma and CSF. 
A meta-analysis of rifampicin pharmacokinetic data from 931 
individuals spanning 30 years concluded that HIV status affects 
the total exposure to rifampicin in the early days of treatment 
(AUC 37.2 mg.h/L in HIV-positive versus 56.7 mg.h/L in 
HIV-negative after standard-dose (10 mg/kg) rifampicin, 
p=0.003)22. HIV associated enteric infections and enteropathy 
causing malabsorption and increased systemic drug clearance 
secondary to low bodyweight may disproportionately affect 
drug concentration in these individuals. In addition, these patients 
are often critically ill on presentation and receive drugs via a 
nasogastric tube, which may further affect drug delivery.
The extent to which blood and CSF rifampicin concentrations 
relate to brain tissue exposure is also unclear. Interesting 
recent data on brain (intralesional) rifampicin pharmacokinetics, 
derived from a rabbit model of experimentally-induced 
TBM using serial noninvasive dynamic 11C-rifampin positron 
emission tomography (PET) over 6 weeks, has shed some light on 
this matter. Rifampin penetration into infected brain lesions is 
limited, spatially heterogeneous, and decreases rapidly as early 
as 2 weeks into treatment. Moreover, rifampin concentrations in 
the cerebrospinal fluid did not correlate well with those in the 
brain lesions. First-in-human 11C-rifampin PET performed in a 
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patient with TBM confirmed these findings. PK modeling using 
this data predicted that higher rifampin doses (≥30 mg/kg) are 
required to achieve adequate intralesional concentrations in 
TBM28.
High dose rifampicin in pulmonary TB
Trials from both the PanACEA consortium and Peru have 
shown encouraging results supporting both the efficacy and 
safety of high dose rifampicin up to a dose of 40 mg/kg29–32. 
The PanACEA multi-arm multistage trial showed that time 
to stable culture conversion in liquid media was faster in 
the 35 mg/kg rifampicin group than in the control group 
(median 48 days vs 62 days, adjusted hazard ratio 1·78; 95% 
confidence interval (CI) 1·22–2·58, p=0·003), but not in other 
experimental arms33. In an additional analysis, increasing 
rifampicin exposure was also associated with shortened time to 
stable culture conversion. The effect did not plateau, indicating 
that doses >35 mg/kg could be yet more effective32.
High-doses rifampicin was also associated with a greater 
estimated fall in M. tuberculosis bacillary load in sputum of 
patients with pulmonary TB at 2 weeks follow up, i.e. high-dose 
rifampicin showed increased ‘early bactericidal activity’29,30. 
Recent analyses of one of these latter trials (the PanACEA 
HIGHRIF1 trial) included doses up to 40 mg/kg, demonstrating 
a further effect of rifampicin exposure on early bactericidal 
activity and clinical trial simulations showed greater early 
bactericidal activity for 50 mg/kg rifampicin34,35. Recent 
evaluations of administration of this 50 mg/kg rifampicin 
dose show that this dose is not well-tolerated. The maximum 
tolerable dose for rifampicin in PTB is therefore set at 
40 mg/kg daily (R. Aarnoutse and L. te Brake, personal 
communication, data from the PanACEA HIGHRIF1 trial).
In summary, data from pulmonary TB have shown that higher 
rifampicin doses, starting with at least 20 mg/kg daily but 
certainly at 35 mg/kg orally, result in strongly increased systemic 
exposures to rifampicin, were safe, tolerated, and resulted in 
increased response, as reflected in improved early bactericidal 
activity and shorter time to culture conversion. These lessons 
learnt in pulmonary TB are relevant to TBM treatment, consider-
ing the key role of rifampicin in TBM treatment and the limited 
CSF penetration seen at standard dose.
Situation of equipoise
Three Indonesian phase II trials have investigated the safety/ 
tolerability of high dose rifampicin to treat TBM. In 2013, 
Ruslami et al., randomised 60 adults with TBM to receive 
2 weeks of intensified treatment with either standard or 33% 
higher intravenous rifampicin dose (13mg/kg), and then either 
400mg, 800mg or no moxifloxacin in a factorial design24. 
They found that a 33% increase in rifampicin dose led to a 
three-fold increase in geometric mean plasma area under the 
curve (AUC
0–6h
), maximum plasma concentration (C
max
) and 
maximum CSF concentration (C
highest
). Although patient numbers 
were small, there was a significantly lower 6-month mortality 
(HR 0.42, 95% CI0.2 to 0.91; p=0.03), a quicker resolution of 
coma (median 4 vs 5 days) and a higher proportion of patients 
with a complete neurological recovery (31% vs 13%) in 
the high dose intravenous rifampicin arm. PK-PD analysis 
revealed that patients who survived in the first two weeks had a 







, with a strong concentration-effect relationship36. 
The effect of rifampicin was similar in both moxifloxacin 
groups, although statistical power was too small to rule out 
a possible interaction between the two interventions. Since 
intravenous rifampicin is an expensive and inconvenient route 
of administration, especially in low- and middle-income 
countries, two further oral rifampicin dose-finding trials were 
undertaken. It was found that a double and triple dose of oral 
rifampicin led to three and five-fold higher geometric mean 
total exposures in plasma, with proportional increases in 
CSF concentrations and without an increase in the incidence 
of grade 3–4 adverse events27,37.
The PK and efficacy data from these three small trials were 
combined and related to each other in a recent combined 
analysis using population PK approach. The PK analysis 
included 133 individuals and 1150 rifampicin concentrations 
(170 from CSF) and the survival analysis included 148 
individuals of whom 58 died and 15 dropped out. Higher 
individual plasma rifampicin exposures (AUC
0–24h
), lower age 
and higher baseline Glasgow coma scale (GCS) scores reduced 
the hazard of death38. Figure 2 shows how simulations predicted 
an increase in 6-month survival from approximately 50% to 
approximately 70% upon increasing the oral rifampicin dose 
from 10 to 30 mg/kg, and predicted that even higher doses 
would further improve survival38. Based on this analysis it 
was concluded that higher rifampicin exposures early during 
treatment substantially decrease the risk of death and that 
optimal dose of rifampicin in treatment of TBM should be 
further investigated in phase III trials.
In contrast, in a large randomised, double-blinded, placebo- 
controlled trial in Vietnam, adults with TBM received an 
intensified TBM regimen containing both 15 mg/kg/day oral 
rifampicin and levofloxacin plus standard isoniazid, pyrazi-
namide and ethambutol or standard of care TBM treatment 
for the first two months of treatment, there was no significant 
difference in 9-month mortality between the two groups 
(HR 0.94; 95% CI, 0.73 to 1.22; P = 0.66), though  there was 
a survival benefit in those with isoniazid monoresistance 
(HR 0.34; 95% CI 0.15 to 0.76; P = 0.01)39,40.
The lack of overall effect in the Vietnam trial could be because 
the oral rifampicin dose was too low. The nested PK/PD study 
in 237 trial participants was published earlier this year and 
aimed to define exposure-response relationships in study 
participants. Rifampin 15mg/kg increased plasma and CSF 
exposures compared to 10mg/kg: day 14 plasma AUC
0–24
 increased 
from 48.2h•mg/L (range 18.2–93.8) to 82.5h•mg/L (range 
8.7–161.0) and CSF AUC
0-24
 from 3.5h•mg/L (range 1.2–9.6) 
to 6.0h•mg/L (range 0.7–15.1). However, within the exposure 
range achieved, no relationship between rifampin exposure and 
survival was seen within the trial41. It is possible, as seen in 
the PTB model34 and in TBM PK-PD model38, a rifampicin 
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Figure 2. Influence of exposure to rifampicin in plasma on survival in Indonesian patients with TBM.
dose of greater than 15mg/kg is required to achieve exposures 
capable of reducing time to culture conversion and improving 
survival, which may explain the lack of exposure-response 
relationship seen in this trial. 
Alternatively, the reduction in mortality seen in the Indonesia 
trial may represent a type-I error due to a small sample size. 
In addition, Indonesian patients had more severe neurological 
dysfunction, with only 7% classified as having grade 1 
disease severity according to the British Medical Research 
Council (BMRC)42 TBM criteria at baseline, compared to 
39% in Vietnam. These conflicting trials create equipoise as to 
whether higher dose rifampicin is beneficial or not; a question 
that HARVEST will be able to answer.
Protocol
1. Hypothesis
Our primary hypothesis is that, among those with TBM, high 
dose oral rifampicin dosed at ~35 mg/kg/day will increase 
plasma, CSF and brain exposure to rifampicin, resulting in more 
rapid mycobacterial clearance, and improved clinical outcomes 
including: 1) survival, 2) more rapid resolution of coma, 
3) improvement in functional status.
2. Main study objectives
2.1 Primary objective. Our primary objective is to determine if high 
dose rifampicin, delivered orally at ~35 mg/kg/day for 8 weeks, 
is safe and improves 6-month survival compared to standard of 
care (rifampicin 10 mg/kg/day) for patients with TBM.
2.2 Secondary objectives. Our secondary objectives are 
six-fold. We will compare the high dose rifampicin to standard 
of care for:
i.    12-month survival
ii.   neurological disability and functional outcomes
iii.  safety and tolerability
iv.  hospital outcomes related to TBM
v.   subsequent neurological deterioration
vi.   management (incidence and outcomes) of drug induced 
liver injury (DILI)
3. Ancillary studies
To maximise research outputs from the trial, several ancillary 
studies are anticipated. These include:
3.1 Clinical pharmacology studies. The objectives will be to 
characterise the PK of rifampicin in plasma and CSF between 
study arms, assess predictors of exposure to rifampicin in 
plasma and CSF, assess the relationship between rifampicin 
concentration and survival and evaluate the impact of high 
dose rifampicin on co-administered antiretroviral therapy 
(ART).
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3.2 Management of DILI. We hypothesise that the current 
guidelines for management of DILI in those with TBM result 
in the premature cessation of rifampicin and isoniazid, both 
critical in early therapy, placing patients at unnecessary risk of 
death and disability.
3.3 Cost effectiveness analysis of the intervention. We will 
perform and economic evaluation of the cost effectiveness of 
the intensified TB treatment intervention from the perspective 
of the health payer in South Africa (middle income country), 
Indonesia (middle income country) and Uganda (low income 
country).
3.4 Archiving blood samples for planned and future studies. 
We will store CSF, plasma, blood, and urine for studies 
related to:
1)   TBM diagnosis. This may include diagnostic testing 
for mycobacterial DNA, RNA, or proteins (e.g. Xpert MTB/RIF 
Ultra, next-generation sequencing, lipoarabinomannan (LAM), 
etc.)
Where consent has been given for host genomic studies we will 
store CSF, plasma, and blood for metagenomic (i.e. DNA and 
RNA) gene sequencing to compare gene expression related to:
2)   TBM prognosis (survival vs. death)
3)   Neurocognitive outcome
4. Design and setting
HARVEST is a parallel group, randomised, placebo-controlled, 
double blind, phase III multicentre clinical trial evaluating 
whether high dose oral rifampicin (~35 mg/kg/day) administered 
during the first 8 weeks of TBM treatment compared to 
standard of care (rifampicin ~10 mg/kg/day) improves outcome 
in TBM (Figure 3). All participants will receive standard 
isoniazid (~5 mg/kg/day), pyrazinamide (~25 mg/kg/day), 
ethambutol (~20 mg/kg/day) plus corticosteroids.
The trial will be set in 5 sites across 3 countries: Hasan 
Sadikin Hospital, Bandung and Dr. Cipto Mangunkusumo 
Hospital, Jakarta in Indonesia; Mulago National Tertiary Referral 
Hospital, Kampala and Mbarara Regional Referral Hospital in 





This time point has been chosen since 95% mortality occurs 
by 6-months, and we anticipate our intervention will have the 
largest impact early in treatment. Mortality will be determined 
by active patient follow-up. Patients lost to follow-up during the 
first 8 weeks will be considered as failures and will count 
towards the primary endpoint. Participants lost to follow-up after 
8 weeks will be censored.
5.2 Secondary endpoints
1. 12-month survival
2. Functional and neurocognitive outcomes
a)    In patients presenting with altered mental status and 
depressed consciousness we will assess the number of 
days from randomisation until GCS 15 is achieved for 
≥2 consecutive days.
b)    We will assess functional outcomes by Liverpool 
Outcome Score at month 6 (Table 2)
c)    We will record quantitative neurocognitive performance 
Z-scores (QNPZ-8) derived from a test battery at 2 and 
12 months (Uganda only). The test battery includes 
Grooved Pegboard test, Colour Trails 1 and 2 tests, 
WAIS-III Digit Symbol test, Finger Tapping test, 
WHO-UCLA Auditory Verbal Learning Test, Semantic 
Verbal Fluency test (category fluency)43
3. Safety and tolerability
We will measure five safety and tolerability end points: 
i) clinical grade 3–4 adverse events (AEs) as classified by 
Division of AIDS (DAIDS) Toxicity Scale, ii) laboratory 
AEs grade 3–4, iii) serious adverse events, iv) DILI (alanine 
transaminase (ALT) or aspartate transaminase (AST) >3x upper 
limit of normal (ULN) with symptoms of hepatitis or >5x ULN 
without symptoms of hepatitis, v) discontinuation of TB 
treatment for >5 days in the first 8 weeks for any cause.
5.3 Tertiary endpoints. Pharmacokinetic parameters and cost- 
effectiveness relate to the ancillary studies and will be reported 
separately from the main trial.
6. Inclusion and exclusion criteria
6.1 Inclusion criteria. We will include adults (≥18 years old) 
who present with a first episode of TBM as clinically suspected 
by the attending physician (≥3 days of meningitis symptoms 
and CSF abnormalities) and TB treatment planned. Written 
informed consent must be obtained by the participant or surrogate 
in the case of altered mental state.
6.2 Exclusion criteria. The participant will be excluded from 
the study if there is jaundice, known liver cirrhosis or elevated 
ALT >5x ULN. Due to dose adjustment of ethambutol and 
pyrazinamide required in renal failure, patients with an 
estimated glomerular filtration rate (eGFR) <30 ml/min will be 
excluded. Participants are ineligible if they have received more 
than five doses of any TB treatment within the previous seven 
days, if they have a known allergy to any standard TB drug 
or have known current or previous rifampicin-resistant 
M. tuberculosis infection. Participants should not be enrolled if 
they have additional active and confirmed CNS infection, have 
a contraindication to steroids, are unlikely or unable to attend 
regular clinic visits or are  pregnant or breastfeeding. Due to 
interactions with rifampicin,  HIV-infected individuals are 
ineligible if they require ongoing use of protease inhibitor-based 
antiretroviral therapy.
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Figure 3. Schematic of study design. Abbreviations: TBM, tuberculous meningitis; BMRC, British Medical Research Council; R, rifampicin; 
H, isoniazid; Z, pyrazinamide; E, ethambutol; FDC, fixed dose combination; caps, capsules; ART, antiretroviral therapy; AE, adverse event; SAE, 
serious adverse event; DILI, drug-induced liver injury.
Table 2. Liverpool outcome score44.
5 Full recovery & normal neurological examination
4 Minor sequelae with mild effects on function or personality change or on medication
3 Moderate sequelae mildly affecting function, probably compatible with independent living
2 Severe sequelae, impairing function sufficient to make patient disabled
1 Death
7. Randomisation and treatment allocation
Adults eligible for enrolment following a diagnostic screening 
lumbar puncture will be approached for enrolment consent. 
Randomisation will occur prior to administration of the sixth 
dose of TB treatment. A computer-generated permutated block 
randomisation algorithm of different sized blocks will randomise 
patients within a 1:1 ratio into the two trial arms.
Randomisation will be stratified by:
1.    Clinical site
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Table 3. Administration of study drug.
Weight










Total R dose 
in placebo 
arm
Dose of other 
TB drugs 
(H/Z/E)
30–37 kg 2 tabs 3 1200mg 300mg 150/800/550
38–54 kg 3 tabs
4
1650mg 450mg 225/1200/825
55–70 kg 4 tabs 1800mg 600mg 300/1600/1100
≥ 71 kg 5 tabs 1950mg 750mg 375/2000/1375
R = rifampicin, H = isoniazid, Z = pyrazinamide, E = ethambutol.
2.    HIV-status
3.    BMRC TBM disease grade I or II/III at time of randomisation
Equal randomisation will occur at each stratum. Randomisation 
schedules will be provided to each study site’s pharmacy in 
a listed sequence. Sequential, unique randomisation codes 
will be recorded on the study entry case report form (CRF) to 
assure no skipping of the randomisation order. All randomised 
participants will initiate their allocated study TB treatment 
within 48 hours of randomisation, and preferably on the same 
day.
The trial will be placebo-controlled and outcomes determined 
by study personnel who are all blinded to treatment alloca-
tion. Unblinding of individual patients will only occur in rare 
emergencies after approval from a Chief Investigator. Hepa-
totoxicity will not require unblinding as they will be managed 
according to the DILI sub-study algorithm, regardless of their 
randomisation arm.
7.1 Treatment discontinuation. In order to prevent delay of urgent 
TBM therapy patients may be enrolled before baseline bloods 
are known to the study team. Study sponsored withdrawals may 
take place before day 15 for one of the following reasons
i.      Baseline ALT >5xULN. Participants can be randomised 
before liver function tests (LFT) results are available 
to the study team, which may be up to 2 days in certain 
sites.
ii.     Baseline eGFR <30 ml/min and fails to rise to 
≥30 ml/min within 72 hours of enrolment. Pyrazinamide 
and ethambutol require renal dosing for long term 
use in those with an eGFR <30 ml/min which would 
complicate intervention and management.
iii.    Rifampicin resistance identified after randomisation. 
Patients with isoniazid-mono-resistant TB may participate 
in the study.
iv.     Confirmed CNS infection other than TBM, who have 
TBM treatment stopped prior to day 15.
8. Interventions
8.1 Meningitis diagnostic tests. Standard of care meningitis test-
ing involves an HIV test (if not already known to be HIV positive), 
a lumbar puncture with routine CSF analysis for white cell 
count and differential, protein, glucose and microscopy (e.g. 
Gram Stain, +/- Ziehl-Neelsen Stain, +/- India ink, cryptococcal 
antigen (HIV-infected participants), TB testing with GeneXpert 
MTB/Rif Ultra, CSF TB culture ± urine TB LAM. Whether 
separate screening consent or lumbar puncture consent is 
required will depend on local practice.
8.2 Antituberculous therapy. HRZE fixed dose combination 
TB treatment consists of rifampicin (R) ~10 mg/kg/day, isoni-
azid (H) ~5 mg/kg/day, pyrazinamide (Z) ~25 mg/kg/day and 
ethambutol (E) 20 mg/kg/day. The intervention arm will consist 
of HRZE fixed dose combination tablets based on weight with 
additional ‘top up’ of four rifampicin 300mg capsules adminis-
tered for the first eight weeks (unless <38 kg, in which case only 
three ‘top up’ rifampicin capsules are given). In the control arm, 
three or four additional placebo tablets will be given according 
to weight (Table 3). After enrolment, participants will receive 
study TB treatment according to random treatment allocation as 
soon as possible, within 24 hours of enrolment. After the 8-week 
intervention period, both arms will be given rifampicin and 
isoniazid according to standard doses during the continuation 
phase of treatment for 7 to 10 months according to national 
guidelines. Medication will be given orally under directly 
observed therapy during hospitalisation, unless the patient 
cannot swallow, in which case tablets will be dispersed in water 
and administered via a nasogastric tube. 
8.3 Antiretroviral therapy. HIV therapy will be provided in 
partnership with local HIV services. HIV-infected participants 
not already receiving ART will be recommended to initiate 
ART at 8-weeks following TB treatment initiation, according to 
international guidelines45. All HIV-infected participants will 
receive cotrimoxazole prophylaxis, unless allergic, according to 
national guidelines.
8.4 Adjunctive corticosteroid treatment. A meta-analysis found 
that adjunctive corticosteroid treatment improve survival among 
HIV-uninfected persons, and as such is recommended for all 
patients with CNS TB according to WHO guidelines46. The 
benefit in HIV-infected persons is less clear and may be 
answered by the ACT-HIV trial currently underway in Vietnam 
and Indonesia (NCT03092817), with results expected in 2020. 
Corticosteroid administration will be standardised for all 
participants as per the trial’s standard operation procedures 
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Table 4. Schedule of events during hospitalisation.









Visit window (days) +3 +3 +3
Screening Consent (Uganda 
only) X
Assess eligibility criteria X
Patient information and 
enrolment consent X
Clinical history and examination
Past medical history X X
Medication review X X X X X X X X X
Document HIV status X
Current symptoms X X X X X X X X X
Physical examination X X X X X X X X
GCS scorea X X X X X X X X X
BMRC disease grade X
Adverse event assessment X X X X X X X X
(SOP), though clinical discretion can be used where medical 
complications arise.
8.5 Blood test monitoring. Routine blood test monitoring will 
occur on day 1, 3, 7, 14, week 4 and week 8 to monitor for 
rifampicin toxicity. See Table 4 and Table 5.
8.6 Pharmacokinetic sampling. In Indonesian and Ugandan 
sites intensive pharmacokinetic sampling will take place on 
day 2, with plasma samples collected at 3 time points, as well 
as a single CSF sample. These sites have experience in prior PK 
studies.
8.7 Neurocognitive testing. In Kampala detailed neurocognitive 
assessment will take place at 2 and 12 months as there is a 
nurse trained and experience in neurocognitive assessment at 
that site.
9. Adverse events and safety reporting
The definitions of the EU Directive 2001/20/EC Article 2 based 
on the principles of the international committee of harmonisa-
tion good clinical practice (ICH GCP) apply to this trial protocol. 
The investigational medicinal product (IMP) is high dose 
rifampicin and the comparator is standard dose rifampicin. All 
adverse events will be assessed for seriousness, causality and 
expectedness. Causality in relation to the IMP is assessed as unre-
lated, unlikely, possible, probably or definite based on temporal 
relationship and clinical judgement. If the event is serious and 
unrelated or unlikely to be related it is classified as a serious 
adverse event (SAE). If the event is classified as possible, prob-
ably or definitely related it is classified as a serious adverse 
reaction (SAR). Expectedness of the adverse reaction is assessed 
using the summary of product characteristics (SPC). An 
unexpected adverse reaction is one not previously reported, 
or more severe or frequently reported in the SPC. If an SAR 
is assessed as unexpected it becomes a suspected unexpected 
serious adverse reaction (SUSAR). Intensity will be assessed 
using the Division of AIDS (DAIDS) Table for Grading 
the Severity of Adult and Paediatric Adverse Events.
The coordinating centre (Infectious Disease Institute, Kampala, 
Uganda) will be notified of all grade 3–4 AEs, SAEs (includ-
ing deaths) and SARs within 72 hours. Investigators will 
notify the coordinating centre of all SAEs occurring from the 
time of randomisation until 6 months (time of primary endpoint). 
SAEs, SARs, and SUSARs will be reported to the coordinating 
centre, local and international Institutional Review Boards 
(IRB) until trial closure, as required by regulatory guidelines. 
The coordinating centre will report SAEs, SARs and SUSARs 
to the regulatory authorities and research ethics committees. 
SAEs and SUSARs will be reported to regulatory authorities 
within 7 days of the coordinating centre becoming aware of the 
event.
Quarterly reports pooled over both arms on subject toxic-
ity will be provided to the trial steering committee (TSC). The 
trial will be monitored by an external and independent data 
and safety monitoring board (DSMB). The independent data 
safety and monitoring board (DSMB) review data after 25%, 
50% and 75% of participants have completed the 2-month 
visit, and will have full access to accumulating data on efficacy, 
safety and treatment group assignment. A Lan-DeMets spending 
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HIV-test (if not known positive) X
Cryptococcal antigen if HIV+ 
(blood) X
Sodium Xc Xg X X
Potassium X
Glucose (bedside) Xc
Creatinined Xc Xg X X
Hepatic panele Xc Xg X X X
Blood Count (including 
differential) X
c Xg X X
CD4 if HIV-positive Xc Xg
Pregnancy test Womenc
Chest radiograph +/-c
Urine sample +/- storagef Xc
Lumbar puncture for Xpert, 
culture and storage after 
enrolment and if not contra-
indicated (SA)h
X
PK/PD sub-study in 
participating sites: sparse PK 
samplingg (plasma x3 and CSF 
x1 sample)
X
Blood / DNA / RNA storage X X (if RIF PK)
X (if ART 





*week 2 visit may be performed as an inpatient or outpatient depending on the time of hospital discharge
a GCS will be captured daily during hospitalisation on a log by study team or routine care providers
b Adverse events will be recorded according to DAIDS toxicity scale
c Provided as standard of care in some of the trial sites. Where not performed as part of SOC the test will be study sponsored.
d Additional renal monitoring will be undertaken in those with abnormal baseline creatinine
e Hepatic panel = alanine aminotransferase (ALT), alkaline phosphatase (ALP) and total bilirubin. Hepatitis BsAg, Hepatitis C Ab will be added if baseline ALT is 
elevated. In the event of DILI hepatic panel will be performed as per DILI SOP.
f Urine sample may be collected from HIV-positive patients during screening for testing with TB-LAM (lipoarobinmannan) as part of TB work-up
g Baseline bloods must occur at either during screening or at enrolment visit. It is possible these visits will be on the same day. If baseline bloods were done at 
screening and enrolment occurs >72 hours later baseline blood tests will be repeated.
h LP may be performed to do initial Xpert/TB culture tests (if not done through routine care) or to repeat these tests to improve diagnostic yield of TBM. 
Investigations requested by the treating physician as part of routine care (e.g. exclusion of additional causes of meningitis as appropriate) may also be 
performed on CSF obtained at this timepoint
GCS = Glasgow come scale, BMRC = British Medical Research Council, PK = pharmacokinetic, PD = pharmacodynamic. 
function analogue of the O’Brien-Fleming boundaries will be 
provided for the 6-month survival outcome with each DSMB 
report. Early termination or protocol modification will be 
considered if the O-Brien-Fleming boundary is crossed. If the 
trial steering  committee, Sponsor, IRB or regulatory authorities 
request the DSMB can modify the frequency of interim analysis.
10. Data collection
10.1 Baseline and subsequent assessment. Participants will be 
enrolled and hospitalised for at least seven days, discharged 
and followed up on a regular schedule until week 52 (Table 4, 
Table 5). Hospitalised patients will be reviewed by a study 
doctor daily on working days in the first week, then 2–3 times 
per week until hospital discharge. During weekends and public 
holidays, the patients can be reviewed by the medical team 
who will alert the study team of any clinical events. Telephone 
follow-up and home visits may be used to minimise inconven-
ience to physically disabled participants. If clinical deterioration 
occurs participants will be seen at unscheduled visits. Addi-
tional laboratory and radiological tests can be undertaken at the 
discretion of the physician with agreement of the site principal 
investigator (PI).
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Table 5. Outpatient Schedule of events.
Study item Wk 2* Wk 4 Wk 8 Wk 12 Wk 18 Wk 24 Wk 36 Wk 52 Sick Visit
Visit window (weeks) (1,3) (3,6) (6, 10) (10, 13) (13, 21) (21, 30) (30, 44) (44, 60) As needed
Dispensing of study 
drug X X X standard fixed dose therapy for 7–10 months as per local guidelines
Interim history X X X X X X X X
AE assessment X X X X X X X X
Medication review X X X X X X X X X
Adherence assessment X X X X X X X X X


























Initiate or switch ARTb X












*week 2 visit may be performed as an inpatient or outpatient depending on the time of hospital discharge
All visits should ideally take place in person but can, in certain circumstances, be done by telephone or via home visit (if patient consents) 
aLiver panel = ALT; alanine aminotransferase, ALP; alkaline phosphatase, total bilirubin
b HIV-infected patients not receiving effective ART. ART initiation via local HIV service and in-line with ART management SOP.
AE = adverse event, CSF = cerebrospinal fluid, ART = antiretroviral therapy 
10.2 Data handling and data management. Source documents 
include detailed CRFs, laboratory and radiology reports, pharmacy 
dispensing records and external medical records. Data entry will 
occur via the DataFax system, whereby paper-based CRFs are 
scanned, emailed to a server and data entered by intelligent 
character recognition. After initial automated error checking, 
secondary review for accuracy will be performed by the DataFax 
team at the Infectious Diseases Institute, Uganda. The DataFax 
system allows for automated data queries to alert for any miss-
ing data on an ongoing basis. This also allows for permanent 
archiving and potential remote review by oversight bodies. 
Study specific forms will be harmonised between all study sites 
enabling multi-site data management. The investigator will 
retain essential study documents completion of the study, as per 
local guidelines. Digital images of the source documents will be 
retained for an indefinite period.
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10.3 Quality control and assurance. Internal and external site 
monitoring will be conducted to ensure that the human subject 
protection, study procedures, laboratory, study intervention 
administration, and data collection processes are of high quality 
and meet the sponsor, ICH E6 and regulatory guidelines. The 
study may be subject to audit by the Infection Diseases Institute, 
Uganda under their remit as sponsor, as well as other regulatory 
bodies to ensure adherence to GCP.
11. Statistical considerations
11.1 Sample size. The target sample size is 500 subjects. The 
randomization will be stratified by site, BMRC TBM severity 
grade (I vs II/III) and HIV-status. The goal for completion of 
enrolment is <30 months based on an accrual of ~200 subjects 
per year. The primary analysis will be intention to treat. Type 1 
error is 0.05 (2-sided) and power = 0.80. We estimate a ~50% 
cumulative death rate with standard TBM treatment. Experience 
in recent studies includes an 8-week mortality of 43% (51/120) 
in TBM patients (88% HIV-infected) in Cape Town12. Ruslami 
et al. reported 8-week mortality of 55% in TBM patients who 
received standard-of-care TB treatment in the Indonesian 
trial, however, 88% of patients were HIV-uninfected27. Two 
large RCTs have further reported mortality of 40–45%3,45 in 
HIV-associated TBM in Vietnam, but with further experience 
and enhanced excellence in care reduced mortality to 27% 
in their most recent 2016 published trial (at the perhaps most 
experienced TBM site in any low and middle-income country)39. 
The potential effect size is based on a conservative effect of 
at least 10% absolute improvement in all-cause 8-week mortality, 
which would be sufficient to change clinical practice. In the 
prior Ruslami et al. trial in Indonesia (n=60), there was a 
56% relative risk reduction in 8-week mortality with 24% 
(7/29) mortality using IV rifampicin vs. 55% (17/31) mortality 
using oral rifampicin therapy27. This 31% absolute reduction 
in mortality may be over-estimated based on the small sample 
size with a 95% CI of 7.3% to 54% mortality reduction. Both 
study-sponsored withdrawals and loss to follow-up are each 
expected to be no more than 5%.
A two-sided log rank time-to-event analysis with an overall 
sample size of 500 subjects (250 in the standard of care arm and 
250 in the high-dose rifampicin arm) achieves 80% power at a 
0.05 significance level to detect a hazard ratio of 0.68 when the 
proportion surviving in the control group is 50%, assuming up 
to 5% lost-to-follow up and no more than 5% study-sponsored 
withdrawals. This equates to a 13% absolute improvement in 
survival. If lost to follow up is less, then power increases slightly. 
Prior lost to follow up rate has been <1% in recent meningitis 
trials. The 12-month follow-up period makes lost-to-follow-up 
more likely, thus we have used an assumption of 5%. For 
survival analyses, participants who are lost-to-follow-up before 
8 weeks will be counted as failures, and participants lost after 
8 weeks censored.
11.2 Primary analysis. The primary analysis will be by intention 
to treat, comparing 6-month survival between the high dose 
rifampicin arm to the standard of care arm. Time-to-event 
methods, including Kaplan-Meier cumulative event curves with 
log-rank tests and proportional hazards regression models will 
be used to summarize excess risk of death. The primary analysis 
will be an unadjusted proportional hazards regression model. 
We will assess the assumption of proportionality of the 
hazards over time, to investigate if there is any evidence of an 
early difference that reverses with additional follow-up. Several 
pre-specified sensitivity analyses will also be performed: a 
model stratified by the randomization strata (clinical site, HIV 
status and BMRC TBM grade), and another model adjusted for 
differences in baseline covariates.
11.3 Secondary analysis. Time-to-event methods will also be used 
for the secondary events of 12-month survival, adverse events 
and re-hospitalisation due to neurological deterioration. Logistic 
regression models will be used to compare the treatment arms 
for binary outcomes (including normalization of mental status 
and all-cause drug discontinuation of more than 5 days), or 
Fisher’s Exact tests if appropriate. Ordinal logistic regression 
models will be used to compare the treatment arms for the 
Liverpool Outcome Score. General linear models or Wilcoxon 
rank-sum tests will be used to compare the treatment arms for 
differences in continuous-valued measurements (including 
QNPZ-8). 
11.4 Planned subgroup analysis. Proportional hazards regression 
models for 6-month survival will also be performed for a priori 
subgroups of interest:
•     Glasgow Coma Score at presentation
•     TBM Diagnostic certainty (Definite/Probable versus 
Possible)4
•     BMRC TBM disease severity3
•     HIV status
•     ART status at study entry
•     Infection with isoniazid mono-resistant Mycobacterium 
tuberculosis strains
•     CSF and plasma rifampicin exposures
11.5 Analysis of ancillary studies. The results of ancillary 
studies will be reported separately from the main trial. Findings 
of the diagnostic sub-study will be reported in line with the 
Standards for the Reporting of Diagnostic Accuracy studies 
(STARD) guidelines.
12. Ethical considerations
12.1 Confidentiality. All participant-related information (including 
CRFs, laboratory specimens, evaluation forms, reports, etc.) will 
be kept strictly confidential. All records will be kept in a secure, 
locked location and only research staff will have access to 
the records. Participants will be identified only by means of a 
coded number specific to each participant. HIV and TB clinic 
records will be kept in the local HIV and TB clinics as per local 
practice.
All computerized databases will identify participants by numeric 
codes only, and will be password-protected. Upon request, 
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participant records will be made available to the study sponsor, 
the sponsor’s monitoring representative, representatives of the 
sponsor and applicable local and national regulatory entities.
12.2 Consent. All informed consent documentation will be read in 
full to potential study participants or their legally acceptable 
surrogate i.e. caregiver or next of kin. Consent will be obtained 
with an approved consent form in English or the local language. 
The potential participant or surrogate will be given sufficient 
time to review, consider and discuss potential questions. 
Participants are still eligible for enrolment having received 
up to 5 days of TB therapy, thus study window for eligibility is 
not a coercive influence. We estimate 50% of the study popula-
tion will have altered mental status at initial hospital presentation, 
therefore may have surrogate consent provided by proxy from 
their caregiver or next of kin.
Upon restoration of normal mental status, subjects enrolled 
with proxy consent will be re-consented. We will request 
permission from the ethics committees to use data of partici-
pants who do not regain ability or die prior to providing consent 
themselves. A person who speaks and understands the language 
of the informed consent document but does not read and 
write can be enrolled in a study by “making their mark” via a 
thumbprint on the informed consent document. The entire 
consent process and thumbprint will be witnessed by an 
impartial, literate third party. The witness’s name, signature 
and relationship will be recorded on the informed consent 
document.
12.3 Sample use and storage. An optional additional storage 
consent will be obtained for long-term storage of blood, CSF 
and urine for the purposes of future research at certain sites 
based on capacity. Absence of this consent does not affect 
eligibility for enrolment or study procedures and storage 
requests required by this protocol.
12.4 Withdrawals. Subjects may withdraw consent at any time 
during the study. Study-sponsored withdrawals may be done 
prior to study day 15 (section 7.1). If subjects are withdrawn 
from the study, for whatever reason, they will be eligible to 
continue to receive TB treatment from a primary TB clinic 
of their choice. Patients enrolled in the study who choose to 
leave hospital early against medical advice may continue to 
participate in the study if they wish. Additional phone calls by 
study personnel will encourage the subject to seek follow up 
TB care and to re-join the trial per the ongoing schedule of 
events. For persons with study-sponsored withdrawal because 
of an alternative brain infection or pathology other than 
TBM, referral will be made to appropriate clinical service. 
Participants will be asked if they would like their accrued data 
to be destroyed.
12.5 Ethical approval. The study coordination centre has 
obtained approval from Mulago Hospital Institutional Review 
Board (MHREC 1554) and the Uganda National Council of 
Science and Technology (HS428ES). In South Africa, approval 
will be obtained from the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal, the Provincial 
Department of Health of KwaZulu-Natal and the South African 
Health Products Regulatory Authority. In Bandung, approval 
will be obtained from Research Ethics Committee of Universitas 
Padjadjaran Bandung, and in Jakarta, approval will be 
obtained from the Research Ethics Committee of the Faculty of 
Medicine Universitas Indonesia and Oxford Tropical Research 
Ethics Committee. Likewise, any future amendments to the 
study protocol will be approved by the trial steering committee 
and then approved by site(s)’ IRB and other regulatory bodies as 
required before being implemented. 
Trial registration. The study was registered on the ISRCTN 
registry on 17 July 2019 under the registration number 
ISRCTN15668391.
13. Trial committees
The trial sponsor is the Infectious Diseases Institute, Uganda. 
The trial management group (TMG) will oversee day-to-day 
management of the trial and is formed of the chief investigators, 
site PIs in Uganda, South Africa, Indonesia, a neurologist and 
statistical advisor. The TMG will meet weekly. The TSC has 
members of the TMG and independent members. The TSC 
provides supervision for the trial and advice through the inde-
pendent Chair. The DSMB will advise the TSC regarding 
continuation, modification or premature closure of the trail. 
The DSMB is independent from the sponsor.
14. Dissemination of findings
We will share results though presentations at scientific confer-
ences and in peer-reviewed open-access journals. Electronic data 
will be stored on the DataFax server housed at the US National 
Institute of Health. Anonymised data can be accessed on written 
request to the data manager after approval by the Sponsor and 
investigators.
Study status
The trial is currently seeking national drug regulatory authority 
approvals.
Discussion
TBM continues to have unacceptably high morbidity and 
mortality despite current WHO recommended therapy. High 
dose rifampicin is safe, tolerable and has favourable CNS 
penetration compared to standard doses. While survival 
benefit has been demonstrated, multiple studies in different 
populations with varying interventions have yielded inconsistent 
results. In addition to Harvest, a further factorial design 
phase III RCT (Intense TBM, NCT04145258) exploring high 
dose rifampicin (35mg/kg) with or without adjunctive linezolid 
and aspirin is planned in Madagascar, Uganda, South Africa 
and Côte d’Ivoire. These complementary phase III randomised, 
placebo-controlled, double-blinded, multi-centre trial will 
definitively answer the question of whether high dose rifampicin 
improves survival in TBM.
Data availability
Underlying data
No data are associated with this article.
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London, UK 
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Marais, Cresswell and collegues present an important, well written, comprehensive trial protocol 
for a phase III multi-site RCT of high vs standard dose rifampicin in the treatment of TBM in HIV-
infected and uninfected patients in Africa and Asia. 
 
The rationale for the study is based on sound phase 2 data, however (as mentioned by Reviewer 1) 
I would urge the authors/investigators to expand a little on the rationale for the choice of the 
35mg/kg rifampicin dose. 
 
The study design, study endpoints and sample size calculation are sound. 
 
I have a few minor suggestions for improvement of the manuscript/protocol:
Introduction - limitations of standard dose rifampicin - are there any data (animal or 
human) on brain (in addition to CSF) penetration of rifampicin? If so, include. 
 
1. 




High dose rifampicin justification: these are key background data to the dosing chosen in 
the trial - which is not sufficiently justified here - suggest expand and/or perhaps include 
diagram summarising any preliminary data from animal/human phase II studies - could 
replace fig 1. 
Specifically need to expand any known data on relationship between dose and 
mycobacterial clearance - is there a threshold? I realise no CFU data in TBM specifically - but 
from animal pulmonary TB models/human EBA data is there a correlation between higher 
doses rif and CFU counts/faster clearance. You mention time to culture conversion - 
important to cite the actual data for all experimental arms in PanACEA. 
 
3. 
Safety of rifampicin: 'It was found that a three-fold increase in oral rifampicin was safe, and 
resulted in a large increase is CSF and plasma exposure' - please be more specific - to what 
dose, and what was size of increase? 
You mention PK data from Vietnam trial awaited - the trial was published in 2016/17- are 
these data now available to you? 
 
4. 
Ancillary studies - management of DILI - it is unclear how management of DILI will be 
assessed as an endpoint/compared between groups (agree with Reviewer 1 comments). 
 
5. 
Inclusion criteria, under case definition -' CSF abnormalities' very non-specific? Suggestive of 
meningitis? We all realise a lot of treatment is empiric - if clinician judgement only then state 
so. Agree with reviewer 1 point about which diagnostics likely to be available to clinicians at 




Is the rationale for, and objectives of, the study clearly described?
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Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Infectious diseases Phase III clinical trial design and conduct in LMICs; 
microbial clearance phase II studies in cryptococcal meningitis.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard.
Author Response 03 Aug 2020
Fiona Cresswell, Mulago College of Health Sciences, Kampala, Uganda 
We thank Dr Bicanic for her expert comments on the protocol and address them in turn 
below. 
 
Comment 1. The rationale for the study is based on sound phase 2 data, however (as 
mentioned by Reviewer 1) I would urge the authors/investigators to expand a little on the 
rationale for the choice of the 35mg/kg rifampicin dose. 
  
Response 1. We have added further detail explaining the rationale for this choice of dose in 
pulmonary TB treatment, as shown below. We have also added further detail to the description of 
the PK-PD model-based analysis using data from Indonesian patients with TBM. Together, we 
hope this makes the rationale for this choice of 35mg/kg dose in the Harvest trial clear. 
  
"The PanACEA multi-arm multistage trial showed that time to stable culture conversion in liquid 
media was faster in the 35 mg/kg rifampicin group than in the control group (median 48 days vs 
62 days, adjusted hazard ratio 1·78; 95% confidence interval (CI) 1·22–2·58, p=0·003), but not in 
other experimental arms. In an additional analysis, increasing rifampicin exposure was also 
associated with shortened time to stable culture conversion. The effect did not plateau, indicating 
that doses >35 mg/kg could be yet more effective. 
High-doses rifampicin was also associated with a greater estimated fall in M. tuberculosis 
bacillary load in sputum of patients with pulmonary TB at 2 weeks follow up, i.e. high-dose 
rifampicin showed increased ‘early bactericidal activity’. Recent analyses of one of these latter 
trials (the PanACEA HIGHRIF1 trial) included doses up to 40 mg/kg, demonstrating a further effect 
of rifampicin exposure on early bactericidal activity and clinical trial simulations showed greater 
early bactericidal activity for 50 mg/kg rifampicin. Recent evaluations of administration of this 50 
mg/kg rifampicin dose show that this dose is not well-tolerated. The maximum tolerable dose for 
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rifampicin in PTB is therefore set at 40 mg/kg daily (R. Aarnoutse and L. te Brake, personal 
communication, data from the PanACEA HIGHRIF1 trial). 
In summary, data from pulmonary TB have shown that higher rifampicin doses, starting with at 
least 20 mg/kg daily but certainly at 35 mg/kg orally, result in strongly increased systemic 
exposures to rifampicin, were safe, tolerated, and resulted in increased response, as reflected in 
improved early bactericidal activity and shorter time to culture conversion. These lessons learnt in 
pulmonary TB are relevant to TBM treatment, considering the key role of rifampicin in TBM 
treatment and the limited CSF penetration seen at standard dose. 
Further, model-based meta-analysis of data from TB meningitis patients in Indonesia predicted 
an increase in 6-month survival from approximately 50% to approximately 70% upon increasing 
the oral rifampicin dose from 10 to 30 mg/kg, and predicted that even higher doses would 
further improve survival” 
 
Comment 2. The study design, study endpoints and sample size calculation are sound. 
 
I have a few minor suggestions for improvement of the manuscript/protocol:  
 
Comment 3. Introduction - limitations of standard dose rifampicin - are there any data 
(animal or human) on brain (in addition to CSF) penetration of rifampicin? If so, include. 
 
Response 3. Thank you for raising this point. There is some interesting recent data on brain 
(intralesional) rifampicin pharmacokinetics derived from rabbit models of experimentally induced 
TBM using serial noninvasive dynamic 11C-rifampin positron emission tomography (PET) over 6 
weeks. Rifampin penetration into infected brain lesions is limited, spatially heterogeneous, and 
decreases rapidly as early as 2 weeks into treatment. Moreover, rifampin concentrations in the 
cerebrospinal fluid did not correlate well with those in the brain lesions. First-in-human 11C-
rifampin PET performed in a patient with TBM confirmed these findings. PK modeling using this 
data predicted that rifampin doses (≥30 mg/kg) were required to achieve adequate 
intralesional concentrations in TBM (Tucker EW, Sci Transl Med, 2018). This information and 
citation have been added to the protocol. 
 
Comment 4. Introduction - fig 1- this figure seems quite generic and out of context and 
could be omitted. 
 
Response 4. We have decided to retain the figure as we are keen to visually highlight that fact 
that the CSF compartment, blood and brain compartment are distinct (yet related).   
 
Comment 5. High dose rifampicin justification: these are key background data to the dosing 
chosen in the trial - which is not sufficiently justified here - suggest expand and/or perhaps 
include diagram summarising any preliminary data from animal/human phase II studies - 
could replace fig 1. Specifically need to expand any known data on relationship between 
dose and mycobacterial clearance - is there a threshold? I realise no CFU data in TBM 
specifically - but from animal pulmonary TB models/human EBA data is there a correlation 
between higher doses rif and CFU counts/faster clearance. You mention time to culture 
conversion - important to cite the actual data for all experimental arms in PanACEA.In the 
absence of clearance data from CSF (animal nor human), we have added further detail 
relating to PK-PD targets from murine PTB and findings relating to clearance in human PTB 
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from the PanACEA studies. 
  
Response 5. In plasma, the historical recommended target peak concentrations of rifampicin are 
8-24mg/L. This historical target is based on rifampicin concentrations typically observed in 
healthy adults (i.e. the reference range after a dose of 10mg/kg orally), and is not optimized 
based on pharmacokinetic-pharmacodynamic (PK-PD) data. It is now accepted that total 
exposure to TB drugs, or the area under the 24-h concentration–time curve (AUC0–24), is more 
relevant to the efficacy of first-line TB drugs. Ideally, AUC0–24 is considered together with the 
minimum inhibitory concentration (MIC) of the mycobacteria to yield an AUC0–24/MIC ratio that is 
supposed to best predict response in murine models (Magis-Escurra, Int J Antimicrob Agents, 
2014). 
  
A large meta-analysis of rifampicin pharmacokinetic data from 70 studies with PTB patients 
found that the mean plasma rifampicin peak concentration at steady state is only 5.79mg/L 
(below the historical target concentration) and doses of >25mg/kg are needed to achieve the PK-
PD target derived from murine studies (AUC/MIC >271) (Stott, J Antimicrob Chemother, 2018). 
  
We have added more detail about the PanACEA studies. The PanACEA multi-arm multistage trial 
showed that time to stable culture conversion in liquid media was faster in the 35 mg/kg 
rifampicin group than in the control group (median 48 days vs 62 days, adjusted hazard ratio 
1·78; 95% confidence interval (CI) 1·22–2·58, p=0·003), but not in other experimental arms. In an 
additional analysis, increasing rifampicin exposure was also associated with shortened time to 
stable culture conversion. The effect did not plateau, indicating that doses >35 mg/kg could be 
yet more effective (though are unlikely to be well tolerated). The exposure-response relationship 
for high-dose rifampicin has been explored by using pharmacokinetic-pharmacodynamic 
modelling based on data from the HIGHRIF studies. Rifampicin exposure was a significant 
covariate on the bacterial kill rate in sputum resulting in increased early bactericidal activity 
(Svensson R. J Infect Dis. 2018; 218(6):991-999). 
  
Comment 6. Safety of rifampicin: 'It was found that a three-fold increase in oral rifampicin 
was safe, and resulted in a large increase is CSF and plasma exposure' - please be more 
specific - to what dose, and what was size of increase? 
You mention PK data from Vietnam trial awaited - the trial was published in 2016/17- are 
these data now available to you? 
 
Response 6. Since intravenous rifampicin is an expensive and inconvenient route of 
administration, especially in low- and middle-income countries, two further oral rifampicin dose-
finding trials were undertaken. We have added further detail to the protocol paper reflecting the 
below results. 
  
In the first follow-up study in 30 Indonesian TBM patients, exposures to and safety of higher oral 
rifampicin doses (750 mg, ca. 17 mg/kg orally; 900 mg, ca. 20 mg/kg orally) were compared with 
the same 600 mg IV rifampicin dose (Yunivita et al. Int J Antimicrob Agents. 2016;48:415-418), as 
studied by Ruslami et al. Both higher oral rifampicin doses resulted in approximately similar 
plasma AUC0-24 but lower plasma Cmax values compared with 600 mg IV. In a second follow-up 
study, 60 Indonesian TBM patients were assigned in a random double-blinded study to standard 
450 mg, 900 mg or 1350 mg (10, 20 and 30 mg/kg for Indonesian subjects) oral rifampicin 
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combined with other TB drugs for 30 days [Dian S. Antimicrob Agents and Chemotherapy. 
2018;62(12):e01004-12]. Double and triple dose of oral rifampicin led to three and five-fold higher 
geometric mean total exposures in plasma, with proportional increases in CSF concentrations, 
without an increase in incidence of grade 3/4 adverse events. Overall, tripling the standard dose 
was considered to be safe. 
  
The PK-PD analysis from the 2016 Vietnamese intensified TB treatment trial were published 
earlier this year (Ding J, Clin Pharmacol Ther, 2020). The nested PK/PD study in 237 trial 
participants was published earlier this year and aimed to define exposure-response relationships 
in study participants. Rifampin 15mg/kg increased plasma and CSF exposures compared to 
10mg/kg: day 14 plasma AUC0-24 increased from 48.2h·mg/L (range 18.2-93.8) to 82.5h·mg/L 
(range 8.7-161.0) and CSF AUC0-24 from 3.5h·mg/L (range 1.2-9.6) to 6.0h·mg/L (range 0.7-15.1). 
However, within the exposure range achieved, no relationship between rifampin exposure and 
survival was seen within the trial. It is possible, as seen in PTB studies (Svennson R), and in TBM 
PK-PD models (Svensson E), a rifampicin dose of greater than 15mg/kg is required to achieve 
exposures capable of reducing time to culture conversion and improving survival, which may 
explain the lack of exposure-response relationship seen in this study. 
 
Comment 7. Ancillary studies - management of DILI - it is unclear how management of DILI 
will be assessed as an endpoint/compared between groups (agree with Reviewer 1 
comments).Thank you for seeking clarity on this. 
 
Response 7. We hope the response given to reviewer 1, and copied here, makes the purpose of 
this sub-study a little clearer. The aim of the sub-study is to determine the safety of a pragmatic 
management strategy, and does not involve comparison between trial arms. Based on safety 
data from prior Indonesian high dose rifampicin studies it appears that the majority (8 of 9) of 
TBM patients who develop transaminitis (ALT of <10x upper limit of normal, ULN), liver enzymes 
settle without interruption of anti-TB drugs. Where transaminitis occurs, we therefore plan to 
closely monitor liver function tests whilst continuing TB treatment unless ALT exceeds a threshold 
of 10x ULN, at which point we will follow an algorithm of stopping and reintroducing TB drugs 
sequentially. Under trial endpoint #6 we use “management of DILI” as a summary term under 
which we aim to describe incidence of DILI, frequency and duration of drug interruptions, hepatic 
outcomes, neurological outcomes. We recognise that “management of DILI” is a little non-specific 
so we have added “incidence and outcome” and will notify IRBs at the time of next regulatory 
amendments.     
 
Comment 8. Inclusion criteria, under case definition -' CSF abnormalities' very non-specific? 
Suggestive of meningitis? We all realise a lot of treatment is empiric - if clinician judgement 
only then states so. Agree with reviewer 1 point about which diagnostics likely to be 
available to clinicians at each site upon which to base inclusion (and subsequent exclusion is 
alternative diagnosis found). This is challenging point and something we discussed at 
length when writing the protocol. All sites will provide a minimum set of CSF tests which 
includes Gram’s stain, bacteriological culture, Xpert MTB/RIF Ultra, TB culture, Cryptococcal 
antigen if HIV-positive. Availability of other tests varies by site (including viral PCR, syphilis 
serology, fungal culture, cytology) and can be performed at clinician discretion. 
  
Response 8. As the CSF picture of TBM varies hugely depending on degree of immunosuppression 
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and ART status we have specified that only one CSF parameter must be abnormal (cell count, 
protein or glucose). Interpretation of CSF findings, within the clinical picture of the patient, and 
eligibility for enrolment is at the discretion of the study physician. 
  
In light of the fact that only around 50% of TBM is microbiologically confirmed and in advanced 
HIV disease it may be necessary to cover a number of CNS infections empirically whilst waiting for 
the results of diagnostics tests and imaging, we have gone on to specify in the full protocol that:
Empiric toxoplasmosis therapy is acceptable○
Positive CSF or blood cryptococcal antigen relating to prior treated cryptococcal meningitis 
and receiving secondary prophylaxis is acceptable if microbiologically-confirmed TBM
○
Study sponsored withdrawal from the trial can take place if there is a microbiological 
confirmation of another CNS infection other than TBM prior to day 15 of the study
○
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Olivier Marcy   
Centre INSERM U1219, Bordeaux Population Health, University of Bordeaux, Bordeaux, France 
This manuscript by Marais, Creswell et al. presents an important randomized clinical trial protocol 
aiming to assess the impact of using high dose oral rifampicin (35mg/kg) versus the usual daily 
dose of 10 mg/kg in the treatment of tuberculosis (TB) meningitis (TBM). As it is well presented by 
the authors in the introduction section of the manuscript, evidence is cumulating on the interest 
of higher doses of rifampicin for pulmonary TB, and the hypothesis is that TBM, the deadliest form 
of tuberculosis, could benefit from higher oral doses of rifampicin. PK and clinical data from phase 
2 studies also confirm the interest of higher doses of rifampicin to decrease the risk of death. As 
stated by the authors “optimal dose of rifampicin in treatment of TBM should be further 
investigated in phase III trials”. 
 
The trial protocol, already approved by national ethics review committees, is globally well 
presented and as mentioned above very well justified. I have a few comments that should be 
taken into account to help the reader understand the study.
I would suggest mentioning clearly in the rationale or hypothesis why the 35 mg/kg dose 
was chosen and refer to publications by Boree and collaborators showing the good safety of 
such high doses. 
 
1. 
Secondary objectives #6 refers to drug-induced liver injury (DILI) management. When one 2. 
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could expect that occurrence of DILI would differ between the two trial arms despite 
previous reassuring previous safety data, it is unclear how management itself is an 
endpoint. One would expect that management of DILI, when it occurs, would be the same 
in both arms i.e. interruption of potentially hepatotoxic drugs above a determined ALT 
elevation threshold. Can the authors clarify what they mean by the possible differences in 
management as an endpoint itself? 
 
In their analysis of the primary endpoints, authors will consider loss to follow-up before 8 
weeks as a failure (death) and loss to follow-up after 8 weeks as censored data. Although 
mortality is maximum between the first few weeks of TBM treatment, the probability of 
survival still decreases steeply beyond 8 weeks. It is therefore very questionable to consider 
loss to follow-up at any time before 6 months as censored data. I would suggest keeping a 
more stringent approach considering loss to follow-up as failure at any time and using 
censoring beyond 8 weeks rather as a sensitivity analysis. 
 
3. 
Authors should clarify what they mean by adverse events graded 3 to 5 using the Division of 
AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. To my 
knowledge, the latest version – corrected 2.1 July 2017, and preceding ones only include 
adverse events graded as severe (3) or life-threatening (4) but no grade 5 events. What 
adverse events are considered as grade 5 by the investigators? Is it an event leading to 
death? If it is the case, how will adjudication be done? 
 
4. 
How extensively will additional active and confirmed CNS infection be investigated? Authors 
mention CrAg, and microscopy with India ink and gram stain but there seems to be 
flexibility left to local practices.They should clarify whether local practices include 
bacteriological culture and investigation for any other viral or fungal infection. 
 
5. 
The sample size is based on a 50% mortality hypothesis that seems reasonable in an HIV-
infected population only but that may appear to be lower in HIV-uninfected patients. 
Authors should clarify what is the expected HIV prevalence in the study population. 
 
6. 
The statistical analysis does not include any plan for interim analysis. I recommend 
clarifying whether the DSMB will be reviewing unblinded data by study arm on the primary 
endpoint and providing a short description of the interim analyses and stopping rules if any. 
 
7. 
Of note, another randomized trial will address the question of the effect on TBM mortality 
of intensified treatment using high dose rifampicin (35 mg/kg) and linezolid with study sites 
in Uganda and South Africa, as well as Côte d’Ivoire and Madagascar (ClinicalTrials.gov 
Identifier: NCT04145258). The trial, designed as a factorial trial will also test the addition of 
low-dose aspirin. I would suggest mentioning this trial in the discussion section and 
commenting on the different options taken by the 2 trials.
8. 
At last, there seems to be a typo when mentioning stratified randomization. I suppose authors are 
referring to BRC TBM disease grade I or II/III at time of randomization rather than “I or II/II”.
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
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Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: TB-HIV co-infection in children and adults, TB meningitis, TB diagnosis in 
children.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 03 Aug 2020
Fiona Cresswell, Mulago College of Health Sciences, Kampala, Uganda 
We thank the reviewer for their time and expertise in reviewing our protocol manuscript. We have 
responded to each comment in turn.  
 
Comment 1. I would suggest mentioning clearly in the rationale or hypothesis why the 35 
mg/kg dose was chosen and refer to publications by Boree and collaborators showing the 
good safety of such high doses. 
 
We refer to and cite Martin Boeree’s 2015 and 2017 paper in the introduction but have gone onto 
add further detail about the PanACEA studies in pulmonary TB and the finding of the meta-
analysis of Indonesian TBM data.  
 
The PanACEA multi-arm multistage trial showed that time to stable culture conversion in liquid 
media was faster in the 35 mg/kg rifampicin group than in the control group (median 48 days vs 
62 days, adjusted hazard ratio 1·78; 95% confidence interval (CI) 1·22–2·58, p=0·003), but not in 
other experimental arms. In an additional analysis, increasing rifampicin exposure was also 
associated with shortened time to stable culture conversion. The effect did not plateau, indicating 
that doses >35 mg/kg could be yet more effective. 
High-doses rifampicin was also associated with a greater estimated fall in M. tuberculosis 
bacillary load in sputum of patients with pulmonary TB at 2 weeks follow up, i.e. high-dose 
rifampicin showed increased ‘early bactericidal activity’. Recent analyses of one of these latter 
trials (the PanACEA HIGHRIF1 trial) included doses up to 40 mg/kg, demonstrating a further effect 
of rifampicin exposure on early bactericidal activity and clinical trial simulations showed greater 
early bactericidal activity for 50 mg/kg rifampicin. Recent evaluations of administration of this 50 
mg/kg rifampicin dose show that this dose is not well-tolerated. The maximum tolerable dose for 
rifampicin in PTB is therefore set at 40 mg/kg daily (R. Aarnoutse and L. te Brake, personal 
communication, data from the PanACEA HIGHRIF1 trial). In summary, data from pulmonary TB 
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have shown that higher rifampicin doses, starting with at least 20 mg/kg daily but certainly at 35 
mg/kg orally, result in strongly increased systemic exposures to rifampicin, were safe, tolerated, 
and resulted in increased response, as reflected in improved early bactericidal activity and 
shorter time to culture conversion. These lessons learnt in pulmonary TB are relevant to TBM 
treatment, considering the key role of rifampicin in TBM treatment and the limited CSF 
penetration seen at standard dose. 
 
Further, model-based meta-analysis of data from TB meningitis patients in Indonesia predicted 
an increase in 6-month survival from approximately 50% to approximately 70% upon increasing 
the oral rifampicin dose from 10 to 30 mg/kg, and predicted that even higher doses would 
further improve survival.  
 
We have added detail to this effect in the manuscript.  
 
Comment 2. Secondary objectives #6 refers to drug-induced liver injury (DILI) management. 
When one could expect that occurrence of DILI would differ between the two trial arms 
despite previous reassuring previous safety data, it is unclear how management itself is an 
endpoint. One would expect that management of DILI, when it occurs, would be the same 
in both arms i.e. interruption of potentially hepatotoxic drugs above a determined ALT 
elevation threshold. Can the authors clarify what they mean by the possible differences in 
management as an endpoint itself? 
 
Thank you for raising this point regarding DILI. The aim of the sub-study is to determine the 
safety of a pragmatic management strategy, and does not involve comparison between trial 
arms. Based on safety data from prior Indonesian high dose rifampicin studies it appears that 
the vast majority (8 of 9) of TBM patients who develop transaminitis (ALT of <10x upper limit of 
normal, ULN), liver enzymes settle without interruption of anti-TB drugs. Where transaminitis 
occurs, we therefore plan to closely monitor liver function tests whilst continuing TB treatment 
unless ALT exceeds a threshold of 10x ULN, at which point we will follow an algorithm of stopping 
and reintroducing TB drugs sequentially. We have detailed the algorithm for the management of 
DILI in an SOP. Under trial endpoint #6 we use “management of DILI” as a summary term under 
which we aim to describe incidence of DILI, frequency and duration of drug interruptions, hepatic 
outcomes, neurological outcomes. We recognise that “management of DILI” is a little non-specific 
so we have added “incidence and outcome” and will notify IRBs at the time of next regulatory 
amendments.     
 
Comment 3. In their analysis of the primary endpoints, authors will consider loss to follow-
up before 8 weeks as a failure (death) and loss to follow-up after 8 weeks as censored data. 
Although mortality is maximum between the first few weeks of TBM treatment, the 
probability of survival still decreases steeply beyond 8 weeks. It is therefore very 
questionable to consider loss to follow-up at any time before 6 months as censored data. I 
would suggest keeping a more stringent approach considering loss to follow-up as failure at 
any time and using censoring beyond 8 weeks rather as a sensitivity analysis. 
 
This is a point we discussed extensively in the protocol writing process and drew on the 
experiences at the sites involved in the trial and available literature. We have recently performed 
a systematic review and meta-analysis of global TBM studies (observational and interventional) 
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which found that over 90% of mortality occurs in the first 12 weeks, with a pooled 12 week 
mortality of 23% and 12 month mortality of 25% (In press, A Stadelman et al. Open Forum 
Infectious Diseases). From prior experience at the trial sites loss to follow-up is a rare occurrence 
(2% in Ugandan meningitis studies) as significant effort is put into tracking patients, supporting 
outpatient follow up or providing home visits for those who are severely disabled. The rare 
occurrences of LTFU are usually in confused meningoencephalitis patients who leave hospital 
against medical advice and without further medical intervention planned, in whom the likelihood 
of survival is extremely low. We therefore think it is acceptable to keep the censoring point in the 
protocol at 8 weeks. We will however do an additional sensitivity analysis counting LTFU at any 
time as an event to see if there is a difference.   
 
Comment 4. Authors should clarify what they mean by adverse events graded 3 to 5 using 
the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events. To my knowledge, the latest version – corrected 2.1 July 2017, and preceding ones 
only include adverse events graded as severe (3) or life-threatening (4) but no grade 5 
events. What adverse events are considered as grade 5 by the investigators? Is it an event 
leading to death? If it is the case, how will adjudication be done? 
 
Thank you for pointing out this error. Indeed, grade 5 = death. This has been corrected in the 
manuscript. 
 
Comment 5. How extensively will additional active and confirmed CNS infection be 
investigated? Authors mention CrAg, and microscopy with India ink and gram stain but 
there seems to be flexibility left to local practices. They should clarify whether local practices 
include bacteriological culture and investigation for any other viral or fungal infection. 
 
The standard of care for routine CSF investigations varies by country and additional tests can be 
performed beyond the routine depending on clinical circumstances and clinician discretion. All 
sites include Gram’s stain and bacteriological culture as routine. In all sites, other tests including 
viral PCR, syphilis serology, fungal culture and cytology can be performed at clinician discretion.  
 
Comment 6. The sample size is based on a 50% mortality hypothesis that seems reasonable 
in an HIV-infected population only but that may appear to be lower in HIV-uninfected 
patients. Authors should clarify what is the expected HIV prevalence in the study 
population. 
 
The expected prevalence of HIV in our study population is 60%.    
 
Comment 7. The statistical analysis does not include any plan for interim analysis. I 
recommend clarifying whether the DSMB will be reviewing unblinded data by study arm on 
the primary endpoint and providing a short description of the interim analyses and 
stopping rules if any. 
 
Thank you for this suggestion. Detail has been added in the safety section on the DSMB functions, 
timing, and early termination considerations.   
 
Comment 8. Of note, another randomized trial will address the question of the effect on 
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TBM mortality of intensified treatment using high dose rifampicin (35 mg/kg) and linezolid 
with study sites in Uganda and South Africa, as well as Côte d’Ivoire and Madagascar 
(ClinicalTrials.gov Identifier: NCT04145258). The trial, designed as a factorial trial will also 
test the addition of low-dose aspirin. I would suggest mentioning this trial in the discussion 
section and commenting on the different options taken by the 2 trials. 
 
Thanks for suggesting this. We have added details to the discussion 
 
Comment 9. At last, there seems to be a typo when mentioning stratified randomization. I 
suppose authors are referring to BRC TBM disease grade I or II/III at time of randomization 
rather than “I or II/II”. 
  
Thank you for spotting this typo! It has been rectified.  
Competing Interests: No competing interests were disclosed.
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